Premium
Micafungin in haematology
Author(s) -
Gamaletsou Maria N.,
Sipsas Nikolaos V.,
Kontoyiannis Dimitrios P.
Publication year - 2012
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2011.02113.x
Subject(s) - micafungin , echinocandin , hematology , medicine , antifungal , hematologic malignancy , aspergillosis , candida infections , intensive care medicine , echinocandins , voriconazole , caspofungin , immunology , dermatology , fluconazole
Summary Invasive fungal infections have emerged as a major cause of increased morbidity and mortality among severely immunosuppressed patients with haematological malignancy. Micafungin, a new member of the echinocandin class, is a valuable addition to the antifungal armamentarium of the 21 st century as it is active against Candida species, Aspergillus species, and other unusual mycoses that frequently affect these high risk patients. Available data on the safety and efficacy of micafungin as prophylaxis, preemptive/empirical treatment, or treatment of documented invasive fungal infection in patients with haematological malignancies are summarized in this review.